Compare · HIMS vs TOI
HIMS vs TOI
Side-by-side comparison of Hims & Hers Health Inc. (HIMS) and The Oncology Institute Inc. (TOI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HIMS and TOI operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- HIMS is the larger of the two at $7.41B, about 14.4x TOI ($512.9M).
- HIMS has been more active in the news (24 items in the past 4 weeks vs 7 for TOI).
- HIMS has more recent analyst coverage (25 ratings vs 8 for TOI).
- Company
- Hims & Hers Health Inc.
- The Oncology Institute Inc.
- Price
- -
- -
- Market cap
- $7.41B
- $512.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 24
- 7
- Recent ratings
- 25
- 8
Hims & Hers Health Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
The Oncology Institute Inc.
The Oncology Institute, Inc. provides cancer awareness, prevention, diagnosis, treatment, and education service. The company offers chemotherapy education, comprehensive lab testing, pain management, financial counseling, end of life counseling, dietary counseling, in-house infusion center, in-house support groups, in-house pharmacy, nutraceuticals, clinical trials, and educational seminars. It also operates the hope, health, and healing center to offer patients alternative and holistic treatments in addition to chemotherapy. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Latest HIMS
- Chief Policy Officer Autor Deborah M. sold $467,128 worth of shares (16,773 units at $27.85) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 48,961 units (SEC Form 4)
- Chief Financial Officer Okupe Oluyemi sold $148,111 worth of shares (4,938 units at $29.99) as part of a pre-agreed trading plan and exercised 4,938 shares at a strike of $5.01 (SEC Form 4)
- Chief Legal Officer Boughton Soleil sold $691,808 worth of shares (25,111 units at $27.55) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 313,964 units (SEC Form 4)
- Chief Legal Officer Boughton Soleil converted options into 42,261 shares and covered exercise/tax liability with 21,500 shares, increasing direct ownership by 7% to 339,075 units (SEC Form 4) to satisfy tax liability
- Chief Medical Officer Carroll Patrick Harrison converted options into 26,187 shares and covered exercise/tax liability with 10,201 shares, increasing direct ownership by 9% to 197,847 units (SEC Form 4) (for tax liability)
- Director Schultz Kare converted options into 6,623 shares, increasing direct ownership by 34% to 26,020 units (SEC Form 4)
- Chief Policy Officer Autor Deborah M. converted options into 32,920 shares and covered exercise/tax liability with 16,147 shares, increasing direct ownership by 34% to 65,734 units (SEC Form 4) to satisfy withholding tax
- CTO Elshenawy Mohamed converted options into 188,285 shares and covered exercise/tax liability with 95,798 shares, increasing direct ownership by 92% to 193,510 units (SEC Form 4) (tax withholding)
- Chief Operating Officer Chi Michael converted options into 86,265 shares and covered exercise/tax liability with 47,702 shares, increasing direct ownership by 9% to 470,687 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Dudum Andrew converted options into 154,993 shares and covered exercise/tax liability with 78,859 shares, increasing direct ownership by 8% to 1,033,177 units (SEC Form 4) to satisfy withholding obligation
Latest TOI
- Director Hively Brad sold $1,946,310 worth of shares (298,853 units at $6.51), decreasing direct ownership by 42% to 411,976 units (SEC Form 4)
- The Oncology Institute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Large owner Chernett Jorey bought $78,480 worth of shares (12,000 units at $6.54), increasing direct ownership by 0.11% to 10,660,858 units (SEC Form 4)
- SEC Form 10-Q filed by The Oncology Institute Inc.
- The Oncology Institute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Oncology Institute Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- The Oncology Institute Rebrands as Starling Oncology
- Director Kaushal Mohit was granted 33,133 shares, increasing direct ownership by 19% to 205,716 units (SEC Form 4)
- Director Mcgeorge Anne was granted 41,165 shares, increasing direct ownership by 14% to 332,535 units (SEC Form 4)
- Director Pacala Mark L was granted 30,120 shares, increasing direct ownership by 12% to 286,881 units (SEC Form 4)